Grifols (NASDAQ:GRFS), a prominent player in the biopharmaceutical industry, announced that its board of directors has granted due diligence access to Brookfield Capital Partners (UK) following a proposal for a corporate takeover.

This development follows discussions held on July 7, 2024, during an extraordinary meeting convened by Grifols' board.

The meeting was prompted by a request from both family shareholders of Grifols and Brookfield to explore a potential acquisition deal that could lead to the delisting of Grifols if finalized.

The family shareholders and Brookfield have agreed to evaluate the feasibility of a joint takeover bid for all share capital of Grifols.

As stated in the announcement made on July 8, the company has not yet confirmed whether the transaction will proceed, nor the terms under which any potential deal would be executed.